ALPMF News and Press, Astellas Pharma Inc From 12/09/19

Merger activity increased with five new deals announced and five deals closing. Deal Statistics New Deals The acquisition of Audentes Therapeutics (BOLD) by Astellas Pharma (ALPMF) for $2.65 billion or $60.00 per share in cash. The acquisition of AK Steel Holding Corporation...

After big biopharma Astellas   (OTC: ALPMY) (OTC: ALPMF) agreed to acquire clinical-stage gene therapy company Audentes Therapeutics (NASDAQ: BOLD) for $3 billion in cash, uniQure 's (NASDAQ: QURE) shares have jumped 13% at 12:15 pm EDT on Tuesday. Although Audentes and uni...

Audentes Therapeutics (NASDAQ: BOLD ) agrees to be acquired by Astellas Pharma ( OTCPK:ALPMF ) for US$60/share in cash, representing a total equity value of ~US$3B; shares are halted. More news on: Audentes Therapeutics, Inc., Astellas Pharma Inc., Astellas Pharma Inc., Healthcare stocks...

Seattle Genetics (NASDAQ: SGEN ) and development partner Astellas Pharma ( OTCPK:ALPMF ) will collaborate with Merck (NYSE: MRK ) on a Phase 3 clinical trial evaluating the combination of antibody-drug conjugate enfortumab vedotin and Keytruda (pembrolizumab) in treatment-naïve p...

FibroGen ( FGEN +15.6% ) rallies on a 6x surge in volume on the heels of safety data on lead drug roxadustat. Pooled results from six Phase 3 studies evaluating the candidate for the treatment of anemia in CKD patients showed a safety profile comparable to placebo, putting investors at e...

Shares of FibroGen ( FGEN ) have risen by 80% since I called the stock a Strong Buy back in 2016, noting that lead program roxadustat (a hypoxia-inducible factor-prolyl hydroxylase or HIF-PH inhibitor) offers several benefits over conventional injectable anemia treatments, including reductio...

ESSA Pharma Inc. (EPIX) [TSX-V: EPI] is a Canadian/U.S. pre-clinical stage pharmaceutical company focused on the development of novel treatments of prostate cancer in patients whose disease is progressing despite treatment with current therapies, including abiraterone and enzalutamide. On ...

The FDA accepts  under Priority Review status Seattle Genetics' (NASDAQ: SGEN ) marketing application for antibody-drug conjugate enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer who have received a PD-1/L1 inhibitor and who have received a platinum...

Astellas Pharma ( OTCPK:ALPMF ) and collaboration partner Pfizer ( PFE +1% ) announce that the FDA has granted Priority Review status for the latter's supplemental marketing application for Xtandi (enzalutamide) for the treatment of metastatic hormone-sensitive prostate cancer. More ne...

Results from the Phase 3 FLAURA study evaluating AstraZeneca's (NYSE: AZN ) Tagrisso (osimertinib) in treatment-naive patients with locally advanced/metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC) showed a statistically significant improvement in overall survival (O...